Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 2008 Jul;48(7):1087-95
Date
08/09/2008Pubmed ID
18687081DOI
10.1111/j.1526-4610.2008.01185.xScopus ID
2-s2.0-46749137929 (requires institutional sign-in at Scopus site) 33 CitationsAbstract
The term chronic daily headache refers to a heterogeneous group of headache disorders characterized by a frequency of headaches on > or = 15 days per month. Chronic migraine is a subtype of chronic daily headache. The prevalence of chronic migraine is approximately 1%. Baseline attack frequency and acute medication overuse have been identified as potential risk factors for the progression of migraine from an episodic disorder to a chronic condition. There is an unmet patient need for effective and safe treatments for patients with chronic migraine, but data from rigorous controlled trials are limited. Previous studies have demonstrated that topiramate is an effective and safe preventive treatment for episodic migraine. In addition, pilot studies have suggested the utility of topiramate for the prevention of chronic migraine. Two randomized, double-blind, placebo-controlled, multicenter trials investigating the efficacy and safety of topiramate in the treatment of patients with chronic migraine have recently been completed. This review presents comparative data from these 2 clinical trials, which suggest that topiramate at a dose of 100 mg daily is effective and generally well tolerated in chronic migraine.
Author List
Silberstein S, Diener HC, Lipton R, Goadsby P, Dodick D, Bussone G, Freitag F, Schwalen S, Ascher S, Morein J, Greenberg S, Biondi D, Hulihan JMESH terms used to index this publication - Major topics in bold
Chronic DiseaseFructose
Headache Disorders
Humans
Migraine Disorders
Randomized Controlled Trials as Topic
Risk Factors
Treatment Outcome
